Despite rapid advances in systemic regimens, reirradiation technology, and an expanding pipeline of therapies for recurrent/metastatic HNSCC, we need evidence-based frameworks to select appropriate candidates and plan safe re-irradiation, reassess resectability and coordinate timing of surgery af

This activity seeks to review innovative clinical trials in the treatment of head and neck cancers from a radiation, surgical and systemic therapy perspective. These trials have novel translational components that may spearhead the next generation of novel clinical trials in these diseases.

Session describes the logistics behind radiopharmaceutical therapy (RPT) administration, starting with drug receipt, preparation, infusion, and finishing with patient release.  The session highlights the role of the qualified medical physicist (QMP) in ensuring safety, quality, and regulatory com

This session reviews the latest science in the field of head and neck cancer.

This session will review the latest science in the field of head and neck cancer.

This panel addresses the emerging evidence transforming the care of advanced head and neck cutaneous malignancy patients, from neoadjuvant and adjuvant immunotherapies to response adaptive surgery and modern approaches to radiation treatment and sentinel node biopsy.

This session explores two essential components of a successful RPT program: authorized user credentialing process and structured training for medical physicists. It includes a step-by-step overview of the regulatory pathway for obtaining AU status, including required training and documentation.

We are in an era of abundant technological innovation. Numerous emerging tools may allow clinicians to evaluate the status of cancer and make clinical decisions faster and less invasively.

This session offers a comprehensive and candid review of the evolution, current impact, and future direction of radiotheranostics, with a particular focus on PSMA targeted imaging and therapy in prostate cancer.

This presentation provides a comprehensive critique of the clinical and preclinical evidence for neoadjuvant immunotherapy. Emphasis is placed on sharpening the definition of immunotherapy, identifying its multi-compartmental effects, and its off-target effects.